In the peg group, all patients collected the target CD34+ cells with a single apheresis with a greater proportion of “optimal” mobilizers (83 vs. 64 %; p = 0.05) showing that a single dose of pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize CD34+ cells in lymphoma patients. This evidence concerns the gene CD34 and lymphoma.